Among the patients with stage IV CRC, patients with KRAS-mutant CRC had a worse OS than patients with KRAS-WT CRC, though the result did not reach statistical significance (20 vs. 34 months, p = 0.10). This evidence concerns the gene KRAS and colorectal carcinoma.